Anixa Biosciences begins patient dosing in third cohort in ongoing phase 1 trial of novel CAR-T therapy for recurrent ovarian cancer: San Jose, California Wednesday, November 20, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback